TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Level of serum 25 hydroxy vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D deficiency detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of exercise compliance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intraoperative Floppy Iris Syndrome incidence
Endpoint domain: Adverse events/effects
Primary endpoint: type, intensity, duration and frequency of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Occurrence of acute and intermediate radiation induced side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Whose Best Confirmed Response is Partial Response (PR) or Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Length of Time for Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: PES Pink Esthetic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Bowel Movements Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: organ steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma alanine transaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in score on Center for Epidemiologic Studies Depression - R (CES-D-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in score on State-Trait Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in score on Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Drinks Felt Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale of Similarity to Alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of sexually transmitted infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum plasma concentration observed (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with adverse events (AEs) and type of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with abnormal laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Liver Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver Fibrosis Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAFLD Fibrosis Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasoactive Inotrope Score (VIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transpulmonary Pressure Gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ischemic-driven target lesion revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Adverse Events Including Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Insulin Independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With HbA1c Less Than or Equal to 6.5 & Free of Severe Hypoglycemic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse events assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of F. prausnitzii per gram faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visual Acuity Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative pulmonary infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Bias between Guardian™ Sensor (3) and YSI™ Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Apnea Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in over ground gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in walking endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cefazolin pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Hyperglycaemia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SB-649868 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driving Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deaths Due to Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Incidence and Severity of Medically Attended Adverse Events (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and Severity of Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Pelvic complete resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sleep Hygiene Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Apnea Knowledge/Apnea Belief Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Patients With Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Social Fluency
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: rate of change of distal common carotid artery far wall intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IKDC-subjective score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Electrodermal Activity (tonic and phasic skin conductance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of abdominal aortic aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Center for Epidemiological Studies-Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body Appreciation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of genetic defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Monoamine Oxidase-B activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in the intensity of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recommended Phase 2 dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Detrimental side effects of prednisolone
Endpoint domain: Adverse events/effects
Primary endpoint: Change in transcapillary escape rate of L125 albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary function (MST value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responses to Dry Mouth Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lipoprotein and plasma oxidizability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxygen Reactive Species (ROS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic adequacy of the tissue sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Seroconversion to A/California/07/2009 (H1N1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Seroconversion to A/Texas/50/2012 (H3N2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Seroconversion to Influenza B/Phuket/3073/2013
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Seroconversion to A/Switzerland/9715293/2013 (H3N2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disease-free Survival (DFS) Rate at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: macular hole closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of γδ T cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: taste and smell impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anemia
Endpoint domain: Adverse events/effects
Primary endpoint: area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal clearance (CLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Chest tube drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Crude healing rate of EE at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight of term infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of nutrients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Viral replication kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Concentration (Cmin) of Ramucirumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Anti-Ramucirumab Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of tests completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ceiling/floor effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variance estimate of baseline/change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-year survivorship
Endpoint domain: Mortality/survival
Primary endpoint: incidence of very early rebleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Metals/metalloids concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intraoperative shivering
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of intraoperative shivering
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With sevoflurane-agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favorable or poor outcome
Endpoint domain: Mortality/survival
Primary endpoint: Local signs of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Assisting Hand Assessment (AHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Occlusion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrent Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Pediatric Pre-Induction Anesthesia Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in β-CIT/neurophysiological measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete sustainable remission for autoimmune haemolytic anemias
Endpoint domain: Mortality/survival
Primary endpoint: Complete sustainable remission for chronic immunologic thrombocytopenic purpura
Endpoint domain: Mortality/survival
Primary endpoint: Risk of NAION
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to Anti-retroviral Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of HIV-infected individuals with renal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Behavior in School Lessons
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in non-invasive pain monitoring index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the concentration-time curve over the dosing interval AUC(0-tau) for sitamaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) for sitamaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum observed plasma concentration (tmax) for sitamaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tremor reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Immunologic response rate as measured by ELISPOT assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicity profile and overall toxicity rates
Endpoint domain: Adverse events/effects
Primary endpoint: Biologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Childhood Asthma Control Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in total Wasserfallen Clinical Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MS related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Retention Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intraoperative bleeding amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D3 receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in motor evoked potential (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in Abnormal Involuntary Movement Scale (AIMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in urine cotinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antibody to capsular polysaccharide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose of sunitinib malate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential time for blood flow to return to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cystoscopic examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absence of reflux in the left subclavian artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vessel sealing failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: days of risky drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: averaged automated blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in Numeric Pain Score (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety including serious adverse events related to ECP
Endpoint domain: Adverse events/effects
Primary endpoint: Change in functional capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With ≥ 4-fold Increase in PRNT50 Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reporting Adverse Events of Severe Intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Clinician's Erythema Assessment (CEA) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Participants Erythema Self-Assessment (PSA) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of eating disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of burn out
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in serum NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intestinal gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toll like receptor 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Right and left atrial volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Take rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Volumetric magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events in the ED
Endpoint domain: Adverse events/effects
Primary endpoint: Increased violence at follow up
Endpoint domain: Adverse events/effects
Primary endpoint: Response to radioiodine therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants free of new or enlarging FLAIR lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Trend of serum uric acid reduction rate (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Trend of serum uric acid levels (mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in the Medical Outcomes Study-Sleep Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline in the Sleep Diary
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants With an Acute Thrombosis Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Who Died Through Day 42
Endpoint domain: Mortality/survival
Primary endpoint: Cerebral Metabolic Rate of Oxygen (CMRO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuronal Reactivity (NR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Enrolling in the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Completing Study Procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetic parameters of nifedipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent Staphylococcus aureus colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IIEF-15 Erectile Function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: public knowledge of biobanking and biospecimen-based research
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: public attitude towards biobanking and biospecimen-based research
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: public willingness to participate in biobank
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Clinical response indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebrospinal Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intratumoral Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Volume at End of Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes